Lacosamide Effects on Pain Management in Human MS Patients
In a Phase 2 randomized trial, lacosamide reduced pain severity in MS patients significantly compared to placebo (P = 0.001), with 90% of participants on lacosamide reporting improvements. Additional benefits included reduced pain interference, total NPSI scores, and enhanced SF-36 scores, with no serious side effects reported.
- Tags
- #Other
- Most relevant to
- —
Why it matters
These findings suggest lacosamide may be an effective option for managing pain in adults with MS, as it statistically improved pain and overall quality of life.
What this does not prove
The study lacked details on sample size and specific methodological aspects, limiting the interpretation of these results.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Interventional
- Participants / samples
- Not reported
- Randomised
- Yes
- Controlled
- Yes
- Primary endpoint met
- Yes
- Relevant MS type
- All
- Publication date
- 2026-09-29
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
- Primary evidenceLacosamide effects on pain management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial. ↗DOI: 10.1016/j.msard.2026.107952
Supporting passages (15)
study phaseMETHODS: This randomized, double-blind, placebo-controlled trial investigated the efficacy of lacosamide in adult patients with definite MS and moderate-to-severe MS-related pain (Brief Pain Inventory [BPI] severity score ≥4).
study designMETHODS: This randomized, double-blind, placebo-controlled trial investigated the efficacy of lacosamide in adult patients with definite MS and moderate-to-severe MS-related pain (Brief Pain Inventory [BPI] severity score ≥4).
subjectsParticipants were randomly assigned (1:1) to receive either lacosamide or a matching placebo for 12 weeks.
randomizedParticipants were randomly assigned (1:1) to receive either lacosamide or a matching placebo for 12 weeks.
controlledMETHODS: This randomized, double-blind, placebo-controlled trial investigated the efficacy of lacosamide in adult patients with definite MS and moderate-to-severe MS-related pain (Brief Pain Inventory [BPI] severity score ≥4).
primary endpoint metCompared to placebo, lacosamide led to a statistically significant decrease in pain severity (P = 0.001), achieving targets of pain below 4 and a 50% reduction.
research categoriesLacosamide effects on pain management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial.
relevant ms typesThis study aims to assess the potential analgesic effects of Lacosamide in individuals with MS.
publication datePublication date: 2026-09-29
interventionLacosamide was titrated weekly to a maximum tolerated dose of 200 mg twice daily.
comparatorRESULTS: The study demonstrated balanced baseline characteristics between treatment groups.
primary endpointThe primary outcome measure was the change in BPI pain severity score from baseline to month three.
follow upParticipants were randomly assigned (1:1) to receive either lacosamide or a matching placebo for 12 weeks.
findingsThe study demonstrated balanced baseline characteristics between treatment groups.
limitationsTitle: Lacosamide effects on pain management in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.